Tellgen Corp

SHE:300642 China Medical Devices
Market Cap
$381.70 Million
CN¥2.80 Billion CNY
Market Cap Rank
#13516 Global
#3480 in China
Share Price
CN¥17.23
Change (1 day)
-1.37%
52-Week Range
CN¥12.09 - CN¥31.30
All Time High
CN¥46.24
Categories
Companies in China Medical Devices
About

Tellgen Corporation researches and develops, manufactures, and distributes IVDs in China and internationally. The company offers tumor markers; cervical cancer and HPV testing kits; Y chromosome microdeletions test kits; autoimmune; tumor methylation; cardiovascular, eugenics, and inflammation. It also provides diagnostic reagents/testing instruments and assembly lines. The company was founded in… Read more

Tellgen Corp (300642) - Net Assets

Latest net assets as of September 2025: CN¥1.53 Billion CNY

Based on the latest financial reports, Tellgen Corp (300642) has net assets worth CN¥1.53 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.00 Billion) and total liabilities (CN¥472.84 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥1.53 Billion
% of Total Assets 76.37%
Annual Growth Rate 28.85%
5-Year Change 19.85%
10-Year Change 689.31%
Growth Volatility 55.1

Tellgen Corp - Net Assets Trend (2012–2024)

This chart illustrates how Tellgen Corp's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Tellgen Corp (2012–2024)

The table below shows the annual net assets of Tellgen Corp from 2012 to 2024.

Year Net Assets Change
2024-12-31 CN¥1.52 Billion -1.15%
2023-12-31 CN¥1.54 Billion +3.72%
2022-12-31 CN¥1.48 Billion +6.04%
2021-12-31 CN¥1.40 Billion +10.24%
2020-12-31 CN¥1.27 Billion +8.38%
2019-12-31 CN¥1.17 Billion +14.11%
2018-12-31 CN¥1.02 Billion +14.32%
2017-12-31 CN¥895.86 Million +210.36%
2016-12-31 CN¥288.65 Million +50.09%
2015-12-31 CN¥192.33 Million +46.76%
2014-12-31 CN¥131.05 Million +37.88%
2013-12-31 CN¥95.04 Million +31.15%
2012-12-31 CN¥72.47 Million --

Equity Component Analysis

This analysis shows how different components contribute to Tellgen Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 16316.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥807.70 Million 53.58%
Common Stock CN¥163.02 Million 10.81%
Other Components CN¥536.77 Million 35.61%
Total Equity CN¥1.51 Billion 100.00%

Tellgen Corp Competitors by Market Cap

The table below lists competitors of Tellgen Corp ranked by their market capitalization.

Company Market Cap
Zhejiang Wellsun Intelligent Tech
SHE:300882
 		$264.71 Million
Hangzhou Fortune Gas Cryogenic Group Co. Ltd. A
SHG:603173
 		$264.71 Million
Blue Water Acquisition Corp. III Class A Ordinary Shares
NASDAQ:BLUW
 		$264.73 Million
CAPITAL BANCORP. DL-01
F:316
 		$264.76 Million
B.Grimm Power Public Company Limited
BK:BGRIM
 		$264.68 Million
PYC Therapeutics Ltd
AU:PYC
 		$264.67 Million
Jiangsu Feymer Technology Co Ltd
SHG:688350
 		$264.42 Million
MARAVAI LIFESC.HLD.A -01
F:MAR
 		$264.39 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Tellgen Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 1,528,514,000 to 1,507,493,000, a change of -21,021,000 (-1.4%).
  • Net income of 34,535,000 contributed positively to equity growth.
  • Dividend payments of 25,618,000 reduced retained earnings.
  • Share repurchases of 12,568,302 reduced equity.
  • Other comprehensive income decreased equity by 83,198,690.
  • Other factors increased equity by 65,828,992.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥34.53 Million +2.29%
Dividends Paid CN¥25.62 Million -1.7%
Share Repurchases CN¥12.57 Million -0.83%
Other Comprehensive Income CN¥-83.20 Million -5.52%
Other Changes CN¥65.83 Million +4.37%
Total Change CN¥- -1.38%

Book Value vs Market Value Analysis

This analysis compares Tellgen Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 1.84x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 28.89x to 1.84x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 CN¥0.60 CN¥17.23 x
2013-12-31 CN¥0.78 CN¥17.23 x
2014-12-31 CN¥1.08 CN¥17.23 x
2015-12-31 CN¥1.58 CN¥17.23 x
2016-12-31 CN¥2.37 CN¥17.23 x
2017-12-31 CN¥6.03 CN¥17.23 x
2018-12-31 CN¥6.31 CN¥17.23 x
2019-12-31 CN¥7.19 CN¥17.23 x
2020-12-31 CN¥7.75 CN¥17.23 x
2021-12-31 CN¥8.48 CN¥17.23 x
2022-12-31 CN¥9.06 CN¥17.23 x
2023-12-31 CN¥9.37 CN¥17.23 x
2024-12-31 CN¥9.37 CN¥17.23 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Tellgen Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 2.29%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 7.91%
  • • Asset Turnover: 0.25x
  • • Equity Multiplier: 1.16x
  • Recent ROE (2.29%) is below the historical average (16.71%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 18.79% 27.96% 0.60x 1.12x CN¥6.37 Million
2013 23.75% 29.39% 0.60x 1.35x CN¥13.07 Million
2014 27.47% 30.46% 0.73x 1.23x CN¥22.90 Million
2015 34.20% 38.83% 0.73x 1.20x CN¥46.55 Million
2016 33.87% 42.28% 0.68x 1.18x CN¥68.90 Million
2017 14.16% 41.87% 0.32x 1.04x CN¥37.23 Million
2018 13.83% 38.84% 0.33x 1.08x CN¥39.28 Million
2019 13.44% 35.57% 0.35x 1.07x CN¥40.15 Million
2020 9.52% 24.62% 0.36x 1.08x CN¥-6.11 Million
2021 11.56% 24.61% 0.44x 1.08x CN¥21.70 Million
2022 8.47% 17.43% 0.43x 1.13x CN¥-22.48 Million
2023 5.85% 16.47% 0.32x 1.10x CN¥-63.45 Million
2024 2.29% 7.91% 0.25x 1.16x CN¥-116.21 Million

Industry Comparison

This section compares Tellgen Corp's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $1,879,733,462
  • Average return on equity (ROE) among peers: 24.67%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Tellgen Corp (300642) CN¥1.53 Billion 18.79% 0.31x $264.70 Million
Shanghai Kehua Bio-Engineering Co Ltd (002022) $792.82 Million 25.77% 0.17x $318.98 Million
Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223) $482.51 Million 20.84% 0.32x $2.79 Billion
Double Medical Technology Inc (002901) $224.61 Million 43.10% 0.32x $404.40 Million
Wuhan Easy Diagnosis Biomedicine Co Ltd Class A (002932) $1.42 Million 98.49% 2.27x $281.14 Million
Lepu Medical Tech Beijing (300003) $12.27 Billion 14.01% 0.69x $2.71 Billion
INKON Life Technology Co Ltd (300143) $1.81 Billion -20.17% 0.37x $637.77 Million
Edan Instruments Inc (300206) $1.26 Billion 7.37% 0.15x $501.55 Million
Guangdong Biolight Meditech Co Ltd (300246) $504.27 Million 13.31% 0.36x $360.97 Million
Beijing Leadman Biochemistry Co Ltd (300289) $1.44 Billion 2.82% 0.20x $267.10 Million
Sinocare Inc (300298) $17.42 Million 41.15% 0.68x $952.60 Million